PDT Partners LLC Decreases Position in uniQure (NASDAQ:QURE)

PDT Partners LLC lowered its holdings in shares of uniQure (NASDAQ:QURE - Free Report) by 45.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 31,098 shares of the biotechnology company's stock after selling 26,101 shares during the quarter. PDT Partners LLC owned 0.06% of uniQure worth $549,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of QURE. Twin Tree Management LP purchased a new position in uniQure during the 4th quarter valued at about $77,000. FNY Investment Advisers LLC purchased a new position in shares of uniQure in the 4th quarter valued at $88,000. ADAR1 Capital Management LLC purchased a new stake in shares of uniQure during the 4th quarter worth $177,000. China Universal Asset Management Co. Ltd. raised its holdings in uniQure by 9.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock worth $195,000 after purchasing an additional 969 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in shares of uniQure by 13.9% in the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after buying an additional 1,503 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company's stock.

Insider Activity

In other news, CEO Matthew C. Kapusta sold 26,727 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total transaction of $285,978.90. Following the completion of the transaction, the chief executive officer now directly owns 571,188 shares in the company, valued at approximately $6,111,711.60. This represents a 4.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Christian Klemt sold 2,916 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12. Following the completion of the transaction, the chief financial officer now directly owns 155,168 shares in the company, valued at $1,756,501.76. The trade was a 1.84 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 90,830 shares of company stock valued at $961,401. 4.74% of the stock is currently owned by insiders.

uniQure Trading Down 5.9 %

uniQure stock traded down $0.67 during trading on Wednesday, reaching $10.81. 2,334,648 shares of the company were exchanged, compared to its average volume of 1,819,327. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The stock's 50 day simple moving average is $12.22 and its two-hundred day simple moving average is $11.99. The company has a market capitalization of $592.02 million, a P/E ratio of -2.18 and a beta of 0.10. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Royal Bank of Canada reissued an "outperform" rating and issued a $24.00 price target on shares of uniQure in a report on Tuesday, January 21st. Chardan Capital reiterated a "buy" rating and issued a $38.00 target price on shares of uniQure in a research report on Tuesday. HC Wainwright reissued a "buy" rating and set a $70.00 target price on shares of uniQure in a report on Monday, April 21st. StockNews.com upgraded uniQure to a "sell" rating in a research note on Tuesday, March 11th. Finally, Wells Fargo & Company lowered their price target on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $38.80.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.